Application 761362

Type
BLA
Sponsor
SANDOZ INC

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761362Jubbontidenosumab-bbdz351(k) InterchangeableRx2026-06-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001JUBBONTIDENOSUMAB-BBDZINJECTABLE;SUBCUTANEOUS60MG/MLNoNo
002WYOSTDENOSUMAB-BBDZINJECTABLE;SUBCUTANEOUS120MG/1.7ML (70MG/ML)NoNo

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 ยท 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
WYOSTDENOSUMABSandoz Inc69e4890d-5dd9-42a5-aa41-ce50635eaed72026-02-20Warnings, Adverse reactionsExact identifier
application number: BLA761362
JUBBONTIDENOSUMABSandoz Inc4bf239bb-c467-4add-b7cf-ea666e4fc6932025-10-30Boxed warning, Warnings, Adverse reactionsExact identifier
application number: BLA761362

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
84019SUPPL 2025-10-31
84018SUPPL 2025-10-31
84002SUPPL 2025-10-31
80016SUPPL 2024-10-28
79987SUPPL 2024-10-25
78914ORIG 2024-06-27
77709ORIG 2024-03-05
77708ORIG 2024-03-05